Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma

Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer

NCT01784978 ·Status: TERMINATED ·Phase: PHASE2

Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)

NCT01069770 ·Status: UNKNOWN ·Phase: PHASE2

Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma

NCT01481870 ·Status: UNKNOWN ·Phase: PHASE3

A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

NCT01391130 ·Status: TERMINATED ·Phase: PHASE2

Identification of Predictive Gene Expression Profile of Sunitinib Response in Metastatic Clear Cell Renal Carcinomas

NCT04415697 ·Status: COMPLETED

Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients

NCT01934452 ·Status: COMPLETED

Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy

NCT00663559 ·Status: COMPLETED ·Phase: PHASE2

Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma

NCT01219751 ·Status: UNKNOWN ·Phase: PHASE2

Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)

NCT00570882 ·Status: COMPLETED ·Phase: PHASE2

Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Renal Cancer

NCT03846128 ·Status: TERMINATED

Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib

NCT03592199 ·Status: UNKNOWN ·Phase: PHASE2

Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib

NCT04076787 ·Status: COMPLETED

A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.

NCT05745142 ·Status: COMPLETED

Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

NCT00130897 ·Status: APPROVED_FOR_MARKETING

A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma

NCT02386111 ·Status: TERMINATED ·Phase: PHASE1

The Pharmacokinetic Variability of Sunitinib in Patients With Metastatic Renal Cancer

NCT02404584 ·Status: COMPLETED

Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma

NCT02555748 ·Status: COMPLETED ·Phase: PHASE4

Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib

NCT00979966 ·Status: COMPLETED ·Phase: PHASE2

Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer

NCT00137423 ·Status: COMPLETED ·Phase: PHASE2

Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery

NCT00747305 ·Status: TERMINATED ·Phase: PHASE1

Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer

NCT01064310 ·Status: COMPLETED ·Phase: PHASE3

Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy

NCT02570789 ·Status: TERMINATED ·Phase: PHASE4

Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule

NCT01499121 ·Status: COMPLETED ·Phase: PHASE2

Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer

NCT00459875 ·Status: COMPLETED ·Phase: PHASE2

Sunitinib Before or After Surgery in Treating Patients With Metastatic Kidney Cancer

NCT00626509 ·Status: UNKNOWN ·Phase: PHASE2